Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a strategic move aimed at bolstering its inflammatory bowel disease (IBD) portfolio.

Eli Lilly and Company announced the successful completion of its acquisition of Morphic Holding, Inc. Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

We recently compiled a list of the 10 Best ESG Stocks To Buy Now. In this article, we are going to take a look at where Eli ...

Eli Lilly also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding a therapy for inflammatory bowel disease to its portfolio. In an effort to make its obesity treatment drug ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

Eli Lilly also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding a therapy for inflammatory bowel disease to its portfolio. In an effort to make its obesity treatment drug, ...

Additionally, Eli Lilly and Company (NYSE:LLY) completed its acquisition of Morphic Holding, Inc., bolstering its immunology portfolio with MORF-057, a therapy for inflammatory bowel disease.